Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos have struck a long-term collaboration focused on improving the bioavailability, efficacy and safety profile of oral therapeutics through nanotechnology.
Japan’s Takeda Pharmaceuticals will invest more than EUR 100 million to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.
Health Canada has released new guidance for industry that will help improve the safe use of health products, making product labels and packages easier for consumers and health professionals to read and understand.
Cancer Research UK has committed £190 million to 13 of its centres over the next five years, marking the largest investment into its network of centres across the UK.
The European Medicines Agency (EMA), in cooperation with the European Commission and the Member States of the European Union, is proposing changes to its existing guideline on first-in-human clinical trials, to further improve the safety of trial participants.
People with advanced breast cancer are set to benefit from a life-extending drug as NICE says it should be available on the NHS.
TraceLink, a track and trace network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, has raised $51.5 million in Series C financing.
A new medicines and pharmaceuticals wholesaler and distributor has been launched to solve difficulties faced by millions of people in Iraq in obtaining modern medicines to treat many illnesses effectively.
The European Commission has granted Orphan Medicinal Product designation in the EU to Pharmalink’s Nefecon (budesonide).
Japan’s Chugai Pharmaceutical Co and Berlin-Chemie Menarini (of the Menarini Group) have entered into a global license agreement for PA799, class I PI3K inhibitor.